Results 1 to 10 of about 3,182,211 (266)

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. [PDF]

J Antimicrob Chemother, 2021
Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality.
Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias SDSG, da Silva CDS, Ferreira AC, Mattos M, Pão CRR, de Freitas CS, Soares VC, Hoelz LVB, Fernandes TVA, Branco FSC, Bastos MM, Boechat N, Saraiva FB, Ferreira MA, Jockusch S, Wang X, Tao C, Chien M, Xie W, Patel D, Garzia A, Tuschl T, Russo JJ, Rajoli RKR, Pedrosa CSG, Vitória G, Souza LRQ, Goto-Silva L, Guimarães MZ, Rehen SK, Owen A, Bozza FA, Bou-Habib DC, Ju J, Bozza PT, Souza TML.   +39 more
europepmc   +2 more sources

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. [PDF]

Life Sci, 2020
Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries.
Elfiky AA.
europepmc   +2 more sources

Direct anti-HCV agents

Acta Pharmaceutica Sinica B, 2016
Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein.
Xing-quan Zhang
openaire   +4 more sources

Screening for anti HCV

Annals of King Edward Medical University, 2016
Purpose of this study is to evaluate the different indications for screening for Anti HCV. This study was carried out in outdoor and indoor department of North Medical Ward of Mayo Hospital, Lahore. This is a non-interventional observational study.
Fatima Mehboob
openalex   +3 more sources

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. [PDF]

PLoS ONE, 2021
Background/aimsHepatitis C Virus (HCV) infection is diagnosed by the presence of antibody to HCV and/or HCV RNA. This study aimed to evaluate the accuracy of anti-HCV titer (S/CO ratio) in predicting HCV viremia in patients with or without hepatitis B ...
Hung-Yin Liu, Yi-Hung Lin, Pei-Ju Lin, Pei-Chien Tsai, Shu-Fen Liu, Ying-Chou Huang, Jia-Jiun Tsai, Ching-I Huang, Ming-Lun Yeh, Po-Cheng Liang, Zu-Yau Lin, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Ming-Lung Yu   +15 more
doaj   +2 more sources

The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations [PDF]

Scientific Reports, 2021
HCV screening depends mainly on a one-assay anti-HCV testing strategy that is subject to an increased false-positive rate in low-prevalence populations.
Yanfang Huang, Huifen Pan, Qin Gao, Panpan Lv, Xiaoqin Xu, Zhen Zhao   +5 more
doaj   +2 more sources

Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies

PLoS ONE, 2014
Background The development of a risk assessment tool for long-term hepatocellular carcinoma risk would be helpful in identifying high-risk patients and providing information of clinical consultation.
Mei–Hsuan Lee, Sheng‐Nan Lu, Yong Yuan, Hwai‐I Yang, Chin–Lan Jen, San‐Lin You, Liyu Wang, Gilbert L’Italien, Chien‐Jen Chen, for the R.E.V.E.A.L.-HCV Study Group   +9 more
openalex   +3 more sources

Anti-HCV drugs in the pipeline [PDF]

Current Opinion in Virology, 2011
Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the most advanced of these are RG7128, an inhibitor of the NS5B polymerase; BMS-790052, an inhibitor of NS5A; and alisporivir, an inhibitor of human cyclophilins. These agents have potent antiviral activity in chronic HCV
Priscilla L, Yang, Min, Gao, Kai, Lin, Qingsong, Liu, Valerie A, Villareal   +4 more
openaire   +3 more sources

Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study [PDF]

Pharmaceuticals
Background: This study evaluated titers and amplitudes of anti-E2 antibodies (anti-E2-Abs) and neutralizing antibodies against hepatitis C virus (HCV; anti-HCV-nAbs) in HIV/HCV-coinfected individuals over five years after successful HCV treatment ...
Daniel Sepúlveda-Crespo, Camilla Volpi, Rafael Amigot-Sánchez, María Belén Yélamos, Cristina Díez, Julián Gómez, Víctor Hontañón, Juan Berenguer, Juan González-García, Rubén Martín-Escolano, Salvador Resino, Isidoro Martínez   +11 more
doaj   +2 more sources

ANTI - HCV : DIAGNOSI DI LABORATORIO

Microbiologia Medica, 2005
-
A. Migliozzi, M.P. Cocco
doaj   +3 more sources